Celgene International II SARL

Inflammatory Bowel Disease

Clinical research in Crohn’s disease and ulcerative colitis centers on maintenance of remission, endoscopic response, and long-term control of moderate to severe intestinal inflammation. The portfolio also includes studies in pediatric Crohn’s disease, with attention to clinical and endoscopic outcomes.

Moderately to severely active Crohn’s disease
Ulcerative colitis
Clinical remission
Endoscopic remission

These programs reflect a focus on chronic gastrointestinal inflammation and disease control across adult and pediatric populations.

Hematologic Malignancies

The sponsor supports trials in relapsed and refractory multiple myeloma, including studies of combination regimens and comparisons with standard-of-care approaches. The research emphasis is on disease progression, treatment response, and survival outcomes in heavily pretreated patients.

Relapsed and refractory multiple myeloma
Combination therapy
Standard of care regimens
Progression-free outcomes

Multiple myeloma studies extend across monotherapy and combination treatment strategies in adult oncology.

Eosinophilic Esophageal Disease

Research in eosinophilic esophagitis focuses on long-term safety and tolerability in adults and adolescents affected by this chronic immune-mediated esophageal disorder. The clinical interest is centered on sustained disease management and symptom control.

Eosinophilic esophagitis
Adolescent and adult patients
Long-term safety
Tolerability

The portfolio addresses a specialized allergic and inflammatory condition with persistent esophageal involvement.

Immune-Mediated Therapy Development

Across its trials, the sponsor is active in immune-mediated disease and oncology research, with a consistent interest in agents evaluated for chronic inflammatory disorders and plasma cell malignancies. The studies include both adult and pediatric populations and span multiple countries and research sites.